Transplant Genomics Release: Studies Presented At World Transplant Congress Support Development Of Biomarker Tests Aimed At Improving Transplant Recipient Care
7/28/2014 9:09:41 AM
BROOKLINE, Mass.--(BUSINESS WIRE)--Studies by the founding scientists of Transplant Genomics Inc. (TGI) to be presented this week at the World Transplant Congress (WTC) are helping lay the groundwork for the company’s development of genomic biomarkers for transplant graft status. The studies are reflective of the pipeline of clinical tests TGI will be commercializing as part of a surveillance program to detect and respond to early signs of graft injury to improve management of organ transplant recipients, with the potential to extend lives and reduce costs of associated healthcare. TGI’s first test will be a blood test used to routinely monitor kidney transplant recipients, indicating when treatment or biopsy is required.
Help employers find you! Check out all the jobs and post your resume.
comments powered by